Last updated 12 days ago

A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

12500 patients around the world

Available in Brazil, Argentina, Puerto Rico, Mexico

Eli Lilly and Company

58Research sites

12500Patients around the world

This study is for people with

Elevated Lipoprotein A

Cardiovascular disease

Established cardiovascular disease

From 18 Years

All Gender

: Have Lipoprotein(a) [Lp(a)] ≥175 nanomoles per liter (nmol/L).
Meet criteria of either 2a or 2b:
Individuals 18 years of age or older with established atherosclerotic cardiovascular disease (ASCVD) with an event or revascularization.
Meet criteria of either 2a or 2b: Individuals 55 years of age or older who are at risk for a first cardiovascular (CV) event and either: Documented coronary artery disease (CAD), carotid stenosis, or peripheral artery disease (PAD) without history of event or revascularization; known familial hypercholesteremia; or a combination of high-risk factors.

: Have had a major cardiovascular event or surgery, such as myocardial infarction (MI), stroke or coronary or peripheral revascularization, < 90 days before screening.
Have uncontrolled hypertension.
Have New York Heart Association class IV heart failure.
Have lipoprotein apheresis within 90 days of screening, or planned lipoprotein apheresis during the study.
Have severe renal failure, defined as Estimated glomerular rate (eGFR) <15 milliliters per minute per 1.73 meters squared (mL/min/1.73m2) at screening Visit 1, or ongoing dialysis.
Have a diagnosis of active nephrotic syndrome, or urine albumin-creatinine ratio (UACR) of ≥5000 mg/g at screening Visit 1.
Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease, or any of these laboratory results as determined by the central laboratory at screening.